AVR Anteris Technologies Global Corp. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$8.49

Period return

+1.92 (+29.22%)

Volume

806.8K

2026-07-21O $8.22 H $8.5 L $7.97 C $8.49MA5 $8.44MA20 $9.5MA60 $8.5MA120 $7.19

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 14.High2 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 03. 27.LowBUY4 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 03. 11.MediumBUY4 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 01. 09.MediumBUY2 years ago
Lake Street: Buy
US analyst rating / recommendation change.
2025. 01. 08.MediumBUY2 years ago
TD Cowen: Buy
US analyst rating / recommendation change.
2025. 01. 07.MediumBUY2 years ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2025. 01. 07.MediumBUY2 years ago
Barclays: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $16 · 4 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Sector: Healthcare
Industry: Medical Instruments & Supplies
HQ: Toowong, QLD, Australia
Fiscal year end: —
Employees: 174
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 14.	After market close (AMC)	$-0.22	—	—	$2.09M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.61	—	—	$556K	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-2.97	—	—	$2.17M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-1.9	—	—	$1.4M	Reported

Anteris Technologies Global Corp.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 15.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 03. 27.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2026. 03. 11.	Wells Fargo	—	Initiate coverage	— → Overweight	—	Wells Fargo: Overweight
2025. 01. 09.	Lake Street	—	Initiate coverage	— → Buy	—	Lake Street: Buy
2025. 01. 08.	TD Cowen	—	Initiate coverage	— → Buy	—	TD Cowen: Buy
2025. 01. 07.	Cantor Fitzgerald	—	Initiate coverage	— → Overweight	—	Cantor Fitzgerald: Overweight